NO801443L - Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur - Google Patents

Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur

Info

Publication number: NO801443L
Authority: NO; Norway
Prior art keywords: virus; cell culture; influenza; cells; trypsin
Prior art date: 1979-05-15

Application number

NO801443A

Other languages

English (en)

Norwegian (no)

Inventor

Karen K Brown

Richard C Stewart

Original Assignee

Cutter Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-05-15

Filing date

1980-05-14

Publication date

1980-11-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21904398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO801443(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1980-05-14 Application filed by Cutter Lab filed Critical Cutter Lab

1980-11-17 Publication of NO801443L publication Critical patent/NO801443L/no

Links

238000000034 method Methods 0.000 title claims description 59
238000004113 cell culture Methods 0.000 title claims description 37
238000004519 manufacturing process Methods 0.000 title claims description 33
239000007788 liquid Substances 0.000 title claims description 28
241000700605 Viruses Species 0.000 claims description 102
210000004027 cell Anatomy 0.000 claims description 66
241000712461 unidentified influenza virus Species 0.000 claims description 56
229960005486 vaccine Drugs 0.000 claims description 41
108090000631 Trypsin Proteins 0.000 claims description 35
102000004142 Trypsin Human genes 0.000 claims description 35
239000012588 trypsin Substances 0.000 claims description 34
241000283073 Equus caballus Species 0.000 claims description 28
206010022000 influenza Diseases 0.000 claims description 28
229960001322 trypsin Drugs 0.000 claims description 26
102000035195 Peptidases Human genes 0.000 claims description 22
108091005804 Peptidases Proteins 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 20
239000001963 growth medium Substances 0.000 claims description 17
208000015181 infectious disease Diseases 0.000 claims description 17
239000004365 Protease Substances 0.000 claims description 14
102000004190 Enzymes Human genes 0.000 claims description 12
108090000790 Enzymes Proteins 0.000 claims description 12
229940088598 enzyme Drugs 0.000 claims description 12
239000012530 fluid Substances 0.000 claims description 11
210000003292 kidney cell Anatomy 0.000 claims description 10
239000002245 particle Substances 0.000 claims description 10
229960003971 influenza vaccine Drugs 0.000 claims description 8
241000282414 Homo sapiens Species 0.000 claims description 7
239000002356 single layer Substances 0.000 claims description 6
241000282465 Canis Species 0.000 claims description 5
102000002322 Egg Proteins Human genes 0.000 claims description 5
108010000912 Egg Proteins Proteins 0.000 claims description 5
241000282898 Sus scrofa Species 0.000 claims description 5
102000005367 Carboxypeptidases Human genes 0.000 claims description 4
108010006303 Carboxypeptidases Proteins 0.000 claims description 4
108010019160 Pancreatin Proteins 0.000 claims description 4
108090000526 Papain Proteins 0.000 claims description 4
108090000284 Pepsin A Proteins 0.000 claims description 4
102000057297 Pepsin A Human genes 0.000 claims description 4
229940055695 pancreatin Drugs 0.000 claims description 4
229940055729 papain Drugs 0.000 claims description 4
235000019834 papain Nutrition 0.000 claims description 4
229940111202 pepsin Drugs 0.000 claims description 4
244000144977 poultry Species 0.000 claims description 4
108090000317 Chymotrypsin Proteins 0.000 claims description 3
108010059712 Pronase Proteins 0.000 claims description 3
229920002125 Sokalan® Polymers 0.000 claims description 3
-1 alum Chemical compound 0.000 claims description 3
229960002376 chymotrypsin Drugs 0.000 claims description 3
229940037003 alum Drugs 0.000 claims description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
150000001720 carbohydrates Chemical class 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229940124873 Influenza virus vaccine Drugs 0.000 claims 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
229910052782 aluminium Inorganic materials 0.000 claims 1
239000006143 cell culture medium Substances 0.000 claims 1
238000007865 diluting Methods 0.000 claims 1
230000000415 inactivating effect Effects 0.000 claims 1
239000006194 liquid suspension Substances 0.000 claims 1
230000001902 propagating effect Effects 0.000 claims 1
230000012010 growth Effects 0.000 description 16
239000002609 medium Substances 0.000 description 15
206010011224 Cough Diseases 0.000 description 10
235000013601 eggs Nutrition 0.000 description 10
235000019419 proteases Nutrition 0.000 description 9
230000000120 cytopathologic effect Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000000725 suspension Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
241000283086 Equidae Species 0.000 description 7
201000010099 disease Diseases 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
229930182816 L-glutamine Natural products 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
239000008121 dextrose Substances 0.000 description 6
239000003797 essential amino acid Substances 0.000 description 6
238000012545 processing Methods 0.000 description 6
241000287828 Gallus gallus Species 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
235000013343 vitamin Nutrition 0.000 description 5
239000011782 vitamin Substances 0.000 description 5
229940088594 vitamin Drugs 0.000 description 5
229930003231 vitamin Natural products 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 3
239000012499 inoculation medium Substances 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
229940049018 mycostatin Drugs 0.000 description 3
229940053050 neomycin sulfate Drugs 0.000 description 3
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
239000000243 solution Substances 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000712431 Influenza A virus Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108010093965 Polymyxin B Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000012832 cell culture technique Methods 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
210000003837 chick embryo Anatomy 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000004264 monolayer culture Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229920000024 polymyxin B Polymers 0.000 description 2
229960005266 polymyxin b Drugs 0.000 description 2
238000012808 pre-inoculation Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000000655 Distemper Diseases 0.000 description 1
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
241001676573 Minium Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
206010051497 Rhinotracheitis Diseases 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000011177 media preparation Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
244000052769 pathogen Species 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

NO801443A 1979-05-15 1980-05-14 Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur NO801443L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3923679A	1979-05-15	1979-05-15

Publications (1)

Publication Number	Publication Date
NO801443L true NO801443L (no)	1980-11-17

Family

ID=21904398

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO801443A NO801443L (no)	1979-05-15	1980-05-14	Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur

Country Status (13)

Country	Link
EP (1)	EP0019218B2 (fr)
JP (1)	JPS55153723A (fr)
AR (1)	AR220838A1 (fr)
AT (1)	ATE16454T1 (fr)
AU (1)	AU535804B2 (fr)
CA (1)	CA1122527A (fr)
DE (1)	DE3071225D1 (fr)
DK (1)	DK154749C (fr)
ES (1)	ES491517A0 (fr)
IL (1)	IL60063A0 (fr)
NO (1)	NO801443L (fr)
RO (1)	RO79525B (fr)
YU (1)	YU41923B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6146873A (en) *	1994-11-10	2000-11-14	Baxter Aktiengesellschaft	Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5753489A (en) *	1994-11-10	1998-05-19	Immuno Ag	Method for producing viruses and vaccines in serum-free culture
EP0791055B1 (fr) *	1994-11-10	2012-01-25	Baxter Healthcare S.A.	Procede de production d'agents biologiques dans un milieu de culture sans proteines
US5698433A (en) *	1994-11-10	1997-12-16	Immuno Ag	Method for producing influenza virus and vaccine
WO1996015232A1 (fr) *	1994-11-16	1996-05-23	St. Jude Children's Research Hospital	Nouveau procede de replication
DE19612967A1 (de) *	1996-04-01	1997-10-02	Behringwerke Ag	Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de)	1996-04-01	2009-12-10	Novartis Vaccines And Diagnostics Gmbh & Co. Kg	MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE10144906B4 (de)	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
US6830917B2 (en)	2001-12-10	2004-12-14	Baxter Healthcare S.A.	Method of isolation and purification of trypsin from pronase protease and use thereof
EP2923711A1 (fr)	2004-11-03	2015-09-30	Novartis Vaccines and Diagnostics, Inc.	Vaccin contre la grippe
US7883844B2 (en)	2006-05-11	2011-02-08	Juridical Foundation The Chemosero-Therapeutic Research Institute	Method for propagating influenza virus
US8506966B2 (en)	2008-02-22	2013-08-13	Novartis Ag	Adjuvanted influenza vaccines for pediatric use
TW201012930A (en) *	2008-06-16	2010-04-01	Intervet Int Bv	Method of replicating viruses in suspension
EP2396032B1 (fr)	2009-02-10	2016-09-28	Seqirus UK Limited	Vaccins contre la grippe comportant des quantités réduites de squalène

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2262962B1 (fr) *	1974-03-05	1977-11-04	Science Union & Cie

1980
- 1980-04-22 CA CA350,366A patent/CA1122527A/fr not_active Expired
- 1980-04-30 AR AR280860A patent/AR220838A1/es active
- 1980-05-08 DE DE8080102525T patent/DE3071225D1/de not_active Expired
- 1980-05-08 EP EP80102525A patent/EP0019218B2/fr not_active Expired - Lifetime
- 1980-05-08 AT AT80102525T patent/ATE16454T1/de not_active IP Right Cessation
- 1980-05-09 AU AU58244/80A patent/AU535804B2/en not_active Expired
- 1980-05-13 YU YU1265/80A patent/YU41923B/xx unknown
- 1980-05-13 JP JP6235780A patent/JPS55153723A/ja active Granted
- 1980-05-13 IL IL60063A patent/IL60063A0/xx unknown
- 1980-05-13 RO RO101109A patent/RO79525B/ro unknown
- 1980-05-14 DK DK212580A patent/DK154749C/da not_active IP Right Cessation
- 1980-05-14 ES ES491517A patent/ES491517A0/es active Granted
- 1980-05-14 NO NO801443A patent/NO801443L/no unknown

Also Published As

Publication number	Publication date
IL60063A0 (en)	1980-07-31
JPH0124769B2 (fr)	1989-05-15
EP0019218A2 (fr)	1980-11-26
AU5824480A (en)	1980-11-20
RO79525B (ro)	1984-09-30
YU41923B (en)	1988-02-29
DK154749C (da)	1989-05-16
DK154749B (da)	1988-12-19
EP0019218A3 (en)	1981-03-25
ES8104405A1 (es)	1981-04-01
AR220838A1 (es)	1980-11-28
YU126580A (en)	1983-12-31
EP0019218B2 (fr)	1995-03-01
DE3071225D1 (en)	1985-12-19
JPS55153723A (en)	1980-11-29
DK212580A (da)	1980-11-16
CA1122527A (fr)	1982-04-27
AU535804B2 (en)	1984-04-05
RO79525A (fr)	1984-07-17
ATE16454T1 (de)	1985-11-15
EP0019218B1 (fr)	1985-11-13
ES491517A0 (es)	1981-04-01

Publication	Publication Date	Title
US4500513A (en)	1985-02-19	Influenza vaccine production in liquid cell culture
CA2250078C (fr)	2009-06-23	Procedes de replication des virus de la grippe dans une culture cellulaire, et virus de la grippe obtenus selon ce procede
US6656720B2 (en)	2003-12-02	Animal cells and processes for the replication of influenza viruses
NO801443L (no)	1980-11-17	Fremgangsmaate til fremstilling av influensavaskine i flytende celle-kultur
CZ105098A3 (cs)	1998-10-14	Vakcína proti chřipce a způsob její přípravy
WO2002024876A2 (fr)	2002-03-28	Vaccin vivant et procede de preparation
AU2002223560A1 (en)	2002-06-20	Live influenza vaccine and method of manufacture
US4338296A (en)	1982-07-06	Influenza virus and process of producing a vaccine therefrom
US20020192234A1 (en)	2002-12-19	Duck pneumovirus and corresponding vaccines
JP2012125261A (ja)	2012-07-05	インフルエンザウイルスを培養物中で複製するための方法
US4302444A (en)	1981-11-24	Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines
USRE33164E (en)	1990-02-13	Influenza vaccine production in liquid cell culture
US3080291A (en)	1963-03-05	Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom
US4571386A (en)	1986-02-18	Feline infectious peritonitis vaccine
US3961046A (en)	1976-06-01	Mumps vaccine and preparation thereof
EP0009277B1 (fr)	1984-04-18	Vaccin combiné actif contre la maladie de Newcastle et contre la baisse de la ponte causée par des virus du genre adéno, procédé de préparation, souches de virus du genre adéno et de la maladie de Newcastle
NZ199561A (en)	1985-07-12	Vaccine against enzootic abortion in ewes
CA1152895A (fr)	1983-08-30	Procede pour preparer de nouvelles souches de virus de la grippe et des vaccins les renfermant
US3962423A (en)	1976-06-08	Live influenza type B virus vaccines and preparation thereof
KR830002615B1 (ko)	1983-12-06	세포배양액내에서 인플루엔자 왁진의 제조방법
US3629396A (en)	1971-12-21	Avian encephalomyelitis vaccine
CA1216234A (fr)	1987-01-06	Preparation de souches modifiees de virus de la diarrhee des bovins et vaccin les contenant
US3432391A (en)	1969-03-11	Attenuated infectious canine hepatitis live virus vaccine and method of producing same
KR20110083126A (ko)	2011-07-20	돼지 인플루엔자 예방을 위한 세포 기원 불활화 백신 및 그의 제조방법
CS202545B2 (en)	1981-01-30	Method of preparing living vaccine from influenza virus for nasal application